Clinical Trial Update: A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study) [Phase 3]

View source ↗

Summary

TSHA-102 gene therapy is being studied in the REVEAL pivotal phase 3 trial for Rett syndrome in females. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rett Syndrome

Drugs mentioned

• TSHA-102

Snippet

Sponsor: Taysha Gene Therapies, Inc. | Conditions: Rett Syndrome | Phase 3 | Status: RECRUITING